The RTS,S vaccine candidate for malaria

References

• WHO. Impact of Malaria Control. In: World Malaria Report 2010. WHO Press, Geneva, Switzerland, 39–62 (2010).
   Google Scholar
• WHO. Impact of Malaria Control. In: World Malaria Report 2009. WHO Press, Geneva, Switzerland, 27–44 (2009).
   Google Scholar
• Snow RW, Craig MH, Newton CR, Steketee RW. The public health burden of Plasmodium falciparum malaria in Africa. Working Paper 11. Disease Control Priorities Project, Bethesda, MD, USA (2003).
   Google Scholar
• Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature216(5111), 160–162 (1967).
   PubMed Web of Science ®Google Scholar
• Clyde DF. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg.24(3), 397–401 (1975).
   PubMed Web of Science ®Google Scholar
• Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci.266(6), 398–403 (1973).
   PubMed Web of Science ®Google Scholar
• Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science207(4426), 71–73 (1980).
   PubMed Web of Science ®Google Scholar
• Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med.151(6), 1504 (1980).
   PubMed Web of Science ®Google Scholar
• Dame J, Williams J, McCutchan T et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science225(4662), 593–599 (1984).
   PubMed Web of Science ®Google Scholar
• Rutgers T, Gordon D, Gathoye AM et al. Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum. Nat. Biotech.6(9), 1065–1070 (1988).
   Google Scholar
• Vreden SGS, Verhave JP, Oettinger T, Sauerwein RW, Meuwissen J. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am. J. Trop. Med. Hyg.45(5), 533 (1991).
   PubMed Web of Science ®Google Scholar
• Gordon DM, McGovern TW, Krzych U et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein–hepatitis B surface antigen subunit vaccine. J. Infect. Dis.171(6), 1576–1585 (1995).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med.336(2), 86 (1997).
   PubMed Web of Science ®Google Scholar
• Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet358(9297), 1927–1934 (2001).
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol.21(1), 23–29 (2009).
   PubMed Web of Science ®Google Scholar
• Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine27(12), 1787–1796 (2009).
   PubMed Web of Science ®Google Scholar
• Kool M, Soullie T, van Nimwegen M et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med.205(4), 869–882 (2008).
   PubMed Web of Science ®Google Scholar
• Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine27(25–26), 3331–3334 (2009).
   PubMed Web of Science ®Google Scholar
• Fox CB, Friede M, Reed SG, Ireton GC. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell. Biochem.53, 303–321 (2010).
   PubMedGoogle Scholar
• Vandepapelière P, Horsmans Y, Moris P et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine26(10), 1375–1386 (2008).
   PubMed Web of Science ®Google Scholar
• Rhee EG, Kelley RP, Agarwal I et al. TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector. J. Virol.84(19), 10413–10419 (2010).
   PubMed Web of Science ®Google Scholar
• Alderson MR, McGowan P, Baldridge JR, Probst P. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res.12(5), 313–319 (2006).
   PubMedGoogle Scholar
• Morefield GL, Hawkins LD, Ishizaka ST, Kissner TL, Ulrich RG. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin. Vaccine Immunol.14(11), 1499–1504 (2007).
   PubMedGoogle Scholar
• Morel S, Didierlaurent A, Bourguignon P et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine29(13), 2461–2473 (2011).
   PubMed Web of Science ®Google Scholar
• Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev. Vaccines8(4), 483–492 (2009).
   PubMed Web of Science ®Google Scholar
• Coler RN, Carter D, Friede M, Reed SG. Adjuvants for malaria vaccines. Parasite Immunol.31(9), 520–528 (2009).
   PubMed Web of Science ®Google Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines6(5), 723–739 (2007).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Kester KE, Krzych U et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis.178(4), 1139–1144 (1998).
   PubMed Web of Science ®Google Scholar
• Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis.183(4), 640–647 (2001).
   PubMed Web of Science ®Google Scholar
• Kester KE, McKinney DA, Tornieporth N et al. A Phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine25(29), 5359–5366 (2007).
   PubMed Web of Science ®Google Scholar
• Kester KE, Cummings JF, Ockenhouse CF et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine26(18), 2191–2202 (2008).
   PubMed Web of Science ®Google Scholar
• Sun P, Schwenk R, White K et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-γ. J. Immunol.171(12), 6961–6967 (2003).
   PubMed Web of Science ®Google Scholar
• Stewart V, Walsh DS, McGrath SM et al. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. Vaccine24(42–43), 6493–6502 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart V, McGrath SM, Walsh DS et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine24(42–43), 6483–6492 (2006).
   PubMed Web of Science ®Google Scholar
• Mettens P, Dubois PM, Demoitié MA et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine26(8), 1072–1082 (2008).
   PubMed Web of Science ®Google Scholar
• Kester K, Cummings J, Ofori-Anyinam O et al. Randomized, double-blind, Phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis.200(3), 337–346 (2009).
   PubMed Web of Science ®Google Scholar
• Doherty JF, Pinder M, Tornieporth N et al. A Phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Am. J. Trop. Med. Hyg.61(6), 865–868 (1999).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Heppner D Jr, Mason CJ et al. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of Western Kenya. Am. J. Trop. Med. Hyg.75(1), 166–170 (2006).
   PubMed Web of Science ®Google Scholar
• Heppner DG, Cummings JF, Ockenhouse CF, Kester KE. New generation vaccines. In: New Generation Vaccines. Marcel Dekker, Inc., New York, NY, USA, 851–859 (2004).
   Google Scholar
• Polhemus ME, Remich SA, Ogutu BR et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE4(7), e6465 (2009).
   PubMed Web of Science ®Google Scholar
• Bojang KA, Olodude F, Pinder M et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine23(32), 4148–4157 (2005).
   PubMed Web of Science ®Google Scholar
• Macete E, Aponte JJ, Guinovart C et al. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique. Trop. Med. Int. Health12(1), 37–46 (2007).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet364(9443), 1411–1420 (2004).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet366(9502), 2012–2018 (2005).
   PubMed Web of Science ®Google Scholar
• Guinovart C, Aponte JJ, Sacarlal J et al. Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a Phase IIb trial in Mozambican children. PLoS ONE4(4), e5165 (2009).
   PubMed Web of Science ®Google Scholar
• Sacarlal J, Aide P, Aponte J et al. Long term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis.200(3), 329–336 (2009).
   PubMed Web of Science ®Google Scholar
• Aponte JJ, Aide P, Renom M et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled Phase I/IIb trial. Lancet370(9598), 1543–1551 (2007).
   PubMed Web of Science ®Google Scholar
• Abdulla S, Oberholzer R, Juma O et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N. Engl. J. Med.359(24), 2533–2544 (2008).
   PubMed Web of Science ®Google Scholar
• Lell B, Agnandji S, von Glasenapp I et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS ONE4(10), e7611 (2009).
   PubMed Web of Science ®Google Scholar
• Owusu-Agyei S, Ansong D, Asante K et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE4(10), e7302 (2009).
   PubMed Web of Science ®Google Scholar
• Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med.359(24), 2521–2532 (2008).
   PubMed Web of Science ®Google Scholar
• Olotu A, Lusingu J, Leach A et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect. Dis.11(2), 102–109 (2011).
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Asante KP, Lyimo J et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J. Infect. Dis.202(7), 1076–1087 (2010).
   PubMed Web of Science ®Google Scholar
• Cummings J, Polhemus M, Kester K et al. Safety, immunogenicity, and efficacy of candidate malaria vaccine containing CSP and MSP-1 antigens. Presented at: 51st Annual Meeting of the American Society of Tropical Medicine and Hygiene. Denver, CO, USA, 10–14 November 2002.
   Google Scholar
• Kester K, Heppner D, Ockenhouse C et al. Double-blind, randomized Phase I/IIa trial of SmithKline Beecham’s candidate malaria vaccines RTS,S+TRAP and TRAP. Presented at: Molecular Approaches to Malaria. Erskine House, Lorne, Victoria, Australia (2000).
   Google Scholar
• Pichyangkul S, Kum-Arb U, Yongvanitchit K et al. Peclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates. Infect. Immun.76(1), 229–238 (2007).
   PubMed Web of Science ®Google Scholar
• Epstein JE, Charoenvit Y, Kester KE et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine22(13–14), 1592–1603 (2004).
   PubMed Web of Science ®Google Scholar
• Wang R, Epstein J, Charoenvit Y et al. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J. Immunol.172(9), 5561–5569 (2004).
   PubMed Web of Science ®Google Scholar
• Dunachie SJ, Walther M, Vuola JM et al. A clinical trial of prime–boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine24(15), 2850–2859 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart VA, McGrath SM, Dubois PM et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun.75(5), 2283–2290 (2007).
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Mintardjo R, Tax D et al. Evaluation of a prime–boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Vaccine27(44), 6226–6233 (2009).
   PubMed Web of Science ®Google Scholar
• Draper SJ, Biswas S, Spencer AJ et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J. Immunol.185(12), 7583–7595 (2010).
   PubMed Web of Science ®Google Scholar